Shandong Weigao Group Medical Polymer Company Limited (WEIGAO GROUP) reported the on-market repurchase of 200,000 H shares on 24 September 2026, according to its Next Day Disclosure Return filed with the Hong Kong Stock Exchange.

The shares were acquired on the Exchange at prices ranging from HKD 3.25 to HKD 3.28, resulting in a volume-weighted average cost of HKD 3.26 and a total cash outlay of HKD 0.65 million. The transaction represents 0.0045 per cent of WEIGAO GROUP’s issued share capital (excluding treasury shares) as of 23 September 2026.

Post-transaction, the company’s outstanding issued shares (excluding treasury shares) declined to 4.46 billion, while treasury shares increased to 66.15 million, keeping the total share count unchanged at 4.52 billion.

The repurchase forms part of the mandate approved on 29 May 2026, which authorises the company to buy back up to 446.46 million shares. Cumulative buybacks under this mandate now stand at 8.82 million shares, equivalent to 1.98 per cent of the share base at the mandate date.

Under Hong Kong listing rules, WEIGAO GROUP is restricted from issuing new shares or disposing of treasury shares until 25 October 2026.